Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emilie Schindler

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
The AAPS Journal|June 22, 2017
A Minimal Continuous-Time Markov Pharmacometric ModelEmilie Schindler, Mats O Karlsson
British Journal of Clinical Pharmacology|October 19, 2013
Population pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical responseBrendan C Bender, Emilie Schindler, Lena E Friberg
Frontiers in Immunology|September 5, 2024
An overview of statistical methods for biomarkers relevant to early clinical development of cancer immunotherapiesDavid Dejardin, Anton Kraxner, Emilie Schindler, et al.
Clinical Pharmacology and Therapeutics|July 18, 2024
PBPK Modeling of Entrectinib and Its Active Metabolite to Derive Dose Adjustments in Pediatric Populations Co-Administered with CYP3A4 InhibitorsKenichi Umehara, Neil Parrott, Emilie Schindler, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 19, 2024
Simulation-based evaluation of the Pharmpy Automatic Model Development tool for population pharmacokinetic modeling in early clinical drug developmentZrinka Duvnjak, Franziska Schaedeli Stark, Valérie Cosson, et al.
Clinical Pharmacology and Therapeutics|May 23, 2023
Response-Based Dosing for Ponatinib: Model-Based Analyses of the Dose-Ranging OPTIC StudyMichael J Hanley, Paul Diderichsen, Benjamin Rich, et al.
Clinical Pharmacology and Therapeutics|September 8, 2022
Population PK and Semimechanistic PK/PD Modeling and Simulation of Relugolix Effects on Testosterone Suppression in Men with Prostate CancerTien-Yi Lee, Philippe Bernard Pierrillas, Yu-Wei Lin, et al.
Cancer Chemotherapy and Pharmacology|February 18, 2015
A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patientsEirini Panoilia, Emilie Schindler, Epaminontas Samantas, et al.
Pharmaceutical Research|April 21, 2018
A Pharmacometric Analysis of Patient-Reported Outcomes in Breast Cancer Patients Through Item Response TheoryEmilie Schindler, Lena E Friberg, Bertram L Lum, et al.
British Journal of Clinical Pharmacology|January 15, 2026
Model-informed drug development to support nemolizumab clinical development in adults and adolescents with moderate to severe atopic dermatitisFloris Fauchet, Anna Largajolli, Petra M Jauslin, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
The AAPS Journal|June 22, 2017
A Minimal Continuous-Time Markov Pharmacometric ModelEmilie Schindler, Mats O Karlsson
British Journal of Clinical Pharmacology|October 19, 2013
Population pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical responseBrendan C Bender, Emilie Schindler, Lena E Friberg
Frontiers in Immunology|September 5, 2024
An overview of statistical methods for biomarkers relevant to early clinical development of cancer immunotherapiesDavid Dejardin, Anton Kraxner, Emilie Schindler, et al.
Clinical Pharmacology and Therapeutics|July 18, 2024
PBPK Modeling of Entrectinib and Its Active Metabolite to Derive Dose Adjustments in Pediatric Populations Co-Administered with CYP3A4 InhibitorsKenichi Umehara, Neil Parrott, Emilie Schindler, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 19, 2024
Simulation-based evaluation of the Pharmpy Automatic Model Development tool for population pharmacokinetic modeling in early clinical drug developmentZrinka Duvnjak, Franziska Schaedeli Stark, Valérie Cosson, et al.
Clinical Pharmacology and Therapeutics|May 23, 2023
Response-Based Dosing for Ponatinib: Model-Based Analyses of the Dose-Ranging OPTIC StudyMichael J Hanley, Paul Diderichsen, Benjamin Rich, et al.
Clinical Pharmacology and Therapeutics|September 8, 2022
Population PK and Semimechanistic PK/PD Modeling and Simulation of Relugolix Effects on Testosterone Suppression in Men with Prostate CancerTien-Yi Lee, Philippe Bernard Pierrillas, Yu-Wei Lin, et al.
Cancer Chemotherapy and Pharmacology|February 18, 2015
A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patientsEirini Panoilia, Emilie Schindler, Epaminontas Samantas, et al.
Pharmaceutical Research|April 21, 2018
A Pharmacometric Analysis of Patient-Reported Outcomes in Breast Cancer Patients Through Item Response TheoryEmilie Schindler, Lena E Friberg, Bertram L Lum, et al.
British Journal of Clinical Pharmacology|January 15, 2026
Model-informed drug development to support nemolizumab clinical development in adults and adolescents with moderate to severe atopic dermatitisFloris Fauchet, Anna Largajolli, Petra M Jauslin, et al.
Pageof 2